Kałas, M.; Stępniewska, E.; Gniedziejko, M.; Leszczyński-Czeczatka, J.; Siemiński, M.
Glucagon-like Peptide-1 Receptor Agonists in the Context of Eating Disorders: A Promising Therapeutic Option or a Double-Edged Sword? J. Clin. Med. 2025, 14, 3122.
https://doi.org/10.3390/jcm14093122
AMA Style
Kałas M, Stępniewska E, Gniedziejko M, Leszczyński-Czeczatka J, Siemiński M.
Glucagon-like Peptide-1 Receptor Agonists in the Context of Eating Disorders: A Promising Therapeutic Option or a Double-Edged Sword? Journal of Clinical Medicine. 2025; 14(9):3122.
https://doi.org/10.3390/jcm14093122
Chicago/Turabian Style
Kałas, Maria, Ewelina Stępniewska, Michał Gniedziejko, Jakub Leszczyński-Czeczatka, and Mariusz Siemiński.
2025. "Glucagon-like Peptide-1 Receptor Agonists in the Context of Eating Disorders: A Promising Therapeutic Option or a Double-Edged Sword?" Journal of Clinical Medicine 14, no. 9: 3122.
https://doi.org/10.3390/jcm14093122
APA Style
Kałas, M., Stępniewska, E., Gniedziejko, M., Leszczyński-Czeczatka, J., & Siemiński, M.
(2025). Glucagon-like Peptide-1 Receptor Agonists in the Context of Eating Disorders: A Promising Therapeutic Option or a Double-Edged Sword? Journal of Clinical Medicine, 14(9), 3122.
https://doi.org/10.3390/jcm14093122